Payload cleaning and analytics: overcoming the challenges of payload cleaning and analytics in ADC manufacturing

Published: 11-Dec-2025

Join Samsung Biologics in partnership with Manufacturing Chemist, for an expert-led session on navigating the unique challenges of ADC Drug Substance manufacturing, including payload handling, flexible manufacturing set-up, and cross contamination management.

Date: 29 January 2026

Time: 15:00 GMT / 16:00 CET / 11:00 EDT

Organiser: Samsung Biologics

Sign up here: https://hpcimedia.com/service/signup-campaign/SAMSUNG29JAN26

Trending Articles

  1. Making Pharmaceuticals 21–22 April 2026 | Exhibition | Coventry, UK
  2. Pharmapack 21–22 January 2026 | Exhibition | Paris, France

You may also like

Payload cleaning and analytics: overcoming the challenges of payload cleaning and analytics in ADC manufacturing

29 January 2026 | Virtual
Manufacturing

Developing strategies for robust chemistry, manufacturing and controls execution for advanced biologics

Chemistry, manufacturing and controls (CMC) is a fundamental discipline for complex drug development projects. It must be rigorously implemented to navigate stringent regulatory requirements before drug approval and commercialisation
Manufacturing

Accelerating technology transfer in biopharmaceutical manufacturing

This article explores how structured, digitally enabled and integrated technology transfer frameworks are accelerating the commercialisation of complex biopharmaceutical modalities by enhancing precision, speed and regulatory readiness
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Driving efficiency in biopharmaceutical manufacturing: the role of CDMOs and advanced technologies

CDMOs and advanced technologies enhance efficiency in biopharmaceutical manufacturing by integrating end-to-end services, leveraging automation and optimising processes and regulatory compliance
Manufacturing

Samsung Bioepis and Nipro sign biosimilar licensing and commercialisation deals

This partnership will expand Samsung Bioepis' Japanese footprint, while providing cost-effective and efficacious biosimilars to the Japanese healthcare landscape
Manufacturing

Samsung Biologics signs $514m manufacturing contract with US-based pharma company

The six year contract manufacturing deal will provide see Samsung Biologics produce pharmaceutical products for an undisclosed, US-based company
Manufacturing

Emirates Biotech to build sustainable production plant for plastic alternatives

The site, which will likely be operational by 2028, will produce renewable and biodegradable plastic alternatives for the manufacturing industries
Subscribe now